Fractyl Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GUTS research report →
About the company
Fractyl Health, Inc. , a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
- CEO
- Harith Rajagopalan
- IPO
- 2024
- Employees
- 102
- HQ
- Burlington, MA, US
Price Chart
- Market Cap
- $55.01M
- P/E
- -0.44
- P/S
- 0.00
- P/B
- 2.70
- EV/EBITDA
- -0.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -4573.89%
- ROIC
- -104.22%
- Revenue
- $0 · -100.00%
- Net Income
- $-140,954,000 · -105.19%
- EPS
- $-1.86 · -14.81%
- Op Income
- $-96,816,000
- FCF YoY
- -35.07%
- 52W High
- $2.44
- 52W Low
- $0.38
- 50D MA
- $0.77
- 200D MA
- $1.09
- Beta
- 2.29
- Avg Volume
- 1.85M
Get TickerSpark's AI analysis on GUTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | Royan Ajay | buy | 23,000 |
| Jun 10, 26 | BRADLEY WILLIAM | buy | 68,493 |
| Jun 10, 26 | BRADLEY WILLIAM | other | 22,500 |
| Jun 10, 26 | Conaway Samuel | other | 22,500 |
| Jun 10, 26 | Royan Ajay | other | 22,500 |
| Jun 10, 26 | Thompson Christopher Charles | other | 22,500 |
| Jun 10, 26 | Elia Marc | other | 22,500 |
| Jun 10, 26 | Barnes Kelly Ann | other | 22,500 |
| Jun 10, 26 | MEANWELL CLIVE | other | 22,500 |
| Jun 10, 26 | Sheffield Ian | buy | 35,000 |
Our GUTS coverage
Recent articles, reports, and earnings notes.
No research on GUTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GUTS report →Similar companies
Peers in the same neighborhood.